



## Anthem Biosciences Limited

(Formerly known as Anthem Biosciences Pvt. Ltd.)  
49, F1 & F2, Canara Bank Road,  
Bommasandra Industrial Area, Phase - I  
Bommasandra, Bengaluru - 560 099  
Karnataka, India  
CIN : L24233KA2006PLC039703  
Tel : + 91 80 6672 4000  
[www.anthembio.com](http://www.anthembio.com)

Date: February 05, 2026

To,  
BSE Limited,  
20th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400001.  
BSE Scrip Code: 544449

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
NSE Scrip Symbol: ANTHEM

**Subject:** Submission of revised press Release on the Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025

Dear Sir/Ma'am

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a revised copy of the Press Release on the Unaudited Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025 due to inadvertent missing out on the complete press release.

The same is also available on the Company's website at <https://www.anthembio.com/investors/>

We request you to kindly take the same on record.

Thanking you,

Yours truly,  
For Anthem Biosciences Limited  
(Formerly known as Anthem Biosciences Private Limited)

DIVYA   
PRASAD Digital signature  
by DIVYA PRASAD  
Date: 2026.02.05  
14:03:19 +05'30'

**Divya Prasad**  
**Company Secretary & Compliance Officer**  
**Membership No: A41438**

**Press Release: Anthem 9MFY26 and Q3FY26 Results**

*For 9MFY26, Consolidated Revenue from Operations stood at ₹15,134 Mn.  
EBITDA for 9MFY26 was ₹6,712 Mn at 41.5% EBITDA Margins.  
PAT at ₹4,020 Mn, with PAT margins at 24.8%.*

*Consolidated Revenue from Operations for the quarter stood at ₹4,232 Mn.  
EBITDA for the quarter was ₹1,907 Mn at 41.8% EBITDA Margins.  
PAT at ₹928 Mn, with PAT margins at 20.3%.*

**Bengaluru, February 05, 2026:** Anthem Biosciences Limited (BSE: 544449 | NSE: ANTHEM | INE0CZ201020), an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”), today announced unaudited results for the third quarter and period ended December 31, 2025 as approved by its Board of Directors.

**9MFY26 and Q3FY26 Financial Highlights:**

Particulars (₹ Mn)	Q3FY26	Q3FY25	YoY	Q2FY26	QoQ	9MFY26	9MFY25	YoY
<b>Revenue from Operations</b>	<b>4,232</b>	<b>4,978</b>	<b>(15.0%)</b>	<b>5,500</b>	<b>(23.1%)</b>	<b>15,134</b>	<b>13,614</b>	<b>11.2%</b>
<b>CRDMO</b>	<b>3,332</b>	<b>4,135</b>	<b>(19.4%)</b>	<b>4,719</b>	<b>(29.4%)</b>	<b>12,599</b>	<b>11,138</b>	<b>13.1%</b>
<b>Specialty Ingredients</b>	<b>899</b>	<b>843</b>	<b>6.7%</b>	<b>781</b>	<b>15.1%</b>	<b>2,535</b>	<b>2,475</b>	<b>2.5%</b>
<b>Other Income</b>	<b>335</b>	<b>244</b>	<b>37.3%</b>	<b>482</b>	<b>(30.5%)</b>	<b>1,046</b>	<b>717</b>	<b>45.9%</b>
<b>Total Revenues</b>	<b>4,567</b>	<b>5,222</b>	<b>(12.5%)</b>	<b>5,982</b>	<b>(23.7%)</b>	<b>16,180</b>	<b>14,330</b>	<b>12.9%</b>
<b>EBITDA</b>	<b>1,907</b>	<b>1,839</b>	<b>3.7%</b>	<b>2,661</b>	<b>(28.3%)</b>	<b>6,712</b>	<b>5,473</b>	<b>22.6%</b>
<b>Profit before tax before exceptional items</b>	<b>1,558</b>	<b>1,610</b>	<b>(3.2%)</b>	<b>2,296</b>	<b>(32.1%)</b>	<b>5,717</b>	<b>4,786</b>	<b>19.5%</b>
<b>Exceptional Items – impact of new labour code</b>	<b>254</b>	<b>n.a</b>	<b>n.a</b>	<b>n.a</b>	<b>n.a</b>	<b>254</b>	<b>n.a</b>	<b>n.a</b>
<b>Profit before tax after exceptional items</b>	<b>1,305</b>	<b>1,610</b>	<b>(19.0%)</b>	<b>2,296</b>	<b>(43.2%)</b>	<b>5,463</b>	<b>4,786</b>	<b>14.2%</b>
<b>Profit after tax</b>	<b>928</b>	<b>1,243</b>	<b>(25.3%)</b>	<b>1,734</b>	<b>(46.5%)</b>	<b>4,020</b>	<b>3,686</b>	<b>9.1%</b>

**9MFY26 Key Financial Highlights:**

- Consolidated Revenue from Operations for the nine months ended Dec 31, 2025 was ₹15,134 Mn
  - CRDMO business delivered ₹12,599 Mn revenues
  - Specialty Ingredients delivered ₹2,535 Mn revenues
- EBITDA was ₹6,712 Mn, with EBITDA margins at 41.5%
  - EBITDA includes Other Income of ₹1,046 Mn (9MFY25: ₹717 Mn)
    - Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹405 Mn (9MFY25: ₹211 Mn)
    - Financial and other Non-Operating Income is ₹641 Mn (9MFY25: ₹506 Mn)
- PBT before exceptions items was ₹5,717 Mn
  - Exceptional item was ₹254 Mn.
  - On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs in this regard. The Company has assessed and made a provision, as an Exceptional Item consistent with the guidance provided by the Institute of Chartered Accountants of India, in the financial results for the quarter and nine months ended December 31, 2025. The Company will continue to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the new Labour Code and will take necessary steps to ensure compliance thereof and also provide appropriate accounting effects, as needed.
- PAT (Profit After Tax) was ₹4,020 Mn, with PAT margins at 24.8%
- Net Cash position as of Dec 31, 2025 is ₹12,312 Mn

### **Q3 FY26 Key Financial Highlights:**

- Consolidated Revenue from Operations was ₹4,232 Mn for the quarter
  - *CRDMO business delivered ₹3,332 Mn revenues*
  - *Specialty Ingredients delivered ₹899 Mn revenues*
- EBITDA was ₹1,907 Mn, with EBITDA margins at 41.8%
  - *EBITDA for Q3 FY26 includes Other Income of ₹335 Mn (Q3 FY25: ₹244 Mn)*
    - *Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹64 Mn (Q3 FY25: ₹98 Mn)*
    - *Financial and other Non-Operating Income is ₹271 Mn (Q3 FY25: ₹146 Mn)*
- PBT before exceptions items was ₹1,558 Mn
  - *Exceptional item on account of new labour code impact was ₹254 Mn.*
- PAT (Profit After Tax) was ₹928 Mn, with PAT margins at 20.3%

Commenting on the results, **Ajay Bhardwaj, Chairman, MD and CEO, Anthem Biosciences Limited**, said: “Our 9MFY26 performance has shown steady progress in revenue terms and with improving margin profile our EBITDA has grown at 23% and PBT before exceptional items has grown around 20%. Our quarterly revenue performance was influenced by the higher base of the same quarter last year, although the margin improvement neutralised the revenue shortfall. The underlying demand remains robust, with our historically strongest quarter still ahead, we are confident of delivering a strong finish to the financial year”.

#### **Earnings Call:**

Anthem Biosciences Limited will conduct earnings call at 2:30 noon (IST) on 5<sup>th</sup> February, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

---

**Date and Time** **5<sup>th</sup> February 2026, 2:30 Noon (IST) / 5:00 pm (SGT/HKT)**

**Universal Dial-in** +91 22 6280 1102 / +91 22 7115 8003

**International Dial-in** Singapore: 8001012045 | HK: 800964448 | USA: 186674 62133 | UK: 08081011573

---

**Diamond Pass link** [Diamond Pass Registration](#)

**About Anthem:** Incorporated in Bangalore on June 13, 2006, Anthem is an innovation-driven and technology-focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. With the three pillars of innovation and technology, high quality standards, and a customer- first approach, Anthem is committed to solving problems in biology and chemistry using technology.

For more information, please visit <https://anthembio.com/investors/>

For further details, please feel free to contact: [investors.abl@anthembio.com](mailto:investors.abl@anthembio.com) | [anthem@adfactorspr.com](mailto:anthem@adfactorspr.com)

---

*Disclaimer: This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Anthem, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.*